ETHMOZINE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jun 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ETHMOZINE is an oral small-molecule tablet approved in 1990 by Takeda for an undisclosed indication. The drug's mechanism of action and therapeutic class remain proprietary or unavailable in this dataset.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting defensive commercial strategies and consolidation of legacy brand teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate minimal active hiring for this product, typical of late-lifecycle assets. Career opportunities are primarily in defensive commercialization, payer negotiation, and generic transition planning rather than growth or innovation roles.
Brand ManagerMedical Science Liaison
Worked on ETHMOZINE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.